1. Home
  2. TRNR vs ENSC Comparison

TRNR vs ENSC Comparison

Compare TRNR & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Interactive Strength Inc.

TRNR

Interactive Strength Inc.

HOLD

Current Price

$1.72

Market Cap

5.9M

Sector

Technology

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.26

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNR
ENSC
Founded
2017
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
6.3M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
TRNR
ENSC
Price
$1.72
$1.26
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
240.2K
417.4K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,774,000.00
$4,487,973.00
Revenue This Year
$578.14
N/A
Revenue Next Year
$130.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
207.36
1.51
52 Week Low
$1.60
$1.26
52 Week High
$39.60
$10.96

Technical Indicators

Market Signals
Indicator
TRNR
ENSC
Relative Strength Index (RSI) 34.55 28.90
Support Level $1.81 $1.26
Resistance Level $2.42 $1.69
Average True Range (ATR) 0.21 0.15
MACD -0.00 -0.02
Stochastic Oscillator 14.63 4.84

Price Performance

Historical Comparison
TRNR
ENSC

About TRNR Interactive Strength Inc.

Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: